Targeting hexokinase 2 in castration-resistant prostate cancer

Aerobic glycolysis, known as the Warburg effect, is one of the hallmarks of cancer cells. We recently reported that the hexokinase 2 (HK2)-mediated Warburg effect is required for castration-resistant prostate cancer that is driven by Pten/p53 deficiency, suggesting that HK2 might be a therapeutic ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Yibin, Lu, Junxuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905284/
https://www.ncbi.nlm.nih.gov/pubmed/27308450
http://dx.doi.org/10.4161/23723556.2014.974465
_version_ 1782437239866785792
author Deng, Yibin
Lu, Junxuan
author_facet Deng, Yibin
Lu, Junxuan
author_sort Deng, Yibin
collection PubMed
description Aerobic glycolysis, known as the Warburg effect, is one of the hallmarks of cancer cells. We recently reported that the hexokinase 2 (HK2)-mediated Warburg effect is required for castration-resistant prostate cancer that is driven by Pten/p53 deficiency, suggesting that HK2 might be a therapeutic target for prostate cancer patients carrying PTEN and p53 mutations.
format Online
Article
Text
id pubmed-4905284
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49052842016-06-15 Targeting hexokinase 2 in castration-resistant prostate cancer Deng, Yibin Lu, Junxuan Mol Cell Oncol Commentary Aerobic glycolysis, known as the Warburg effect, is one of the hallmarks of cancer cells. We recently reported that the hexokinase 2 (HK2)-mediated Warburg effect is required for castration-resistant prostate cancer that is driven by Pten/p53 deficiency, suggesting that HK2 might be a therapeutic target for prostate cancer patients carrying PTEN and p53 mutations. Taylor & Francis 2015-04-30 /pmc/articles/PMC4905284/ /pubmed/27308450 http://dx.doi.org/10.4161/23723556.2014.974465 Text en © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Commentary
Deng, Yibin
Lu, Junxuan
Targeting hexokinase 2 in castration-resistant prostate cancer
title Targeting hexokinase 2 in castration-resistant prostate cancer
title_full Targeting hexokinase 2 in castration-resistant prostate cancer
title_fullStr Targeting hexokinase 2 in castration-resistant prostate cancer
title_full_unstemmed Targeting hexokinase 2 in castration-resistant prostate cancer
title_short Targeting hexokinase 2 in castration-resistant prostate cancer
title_sort targeting hexokinase 2 in castration-resistant prostate cancer
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905284/
https://www.ncbi.nlm.nih.gov/pubmed/27308450
http://dx.doi.org/10.4161/23723556.2014.974465
work_keys_str_mv AT dengyibin targetinghexokinase2incastrationresistantprostatecancer
AT lujunxuan targetinghexokinase2incastrationresistantprostatecancer

Ejemplares similares